Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $40
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $44 to $40.
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $44 to $40.